NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.49
+0.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 19.6M | 18.2M | 12.9M | 15.4M | 13.2M |
| SG&A Expense | 9.2M | 9.4M | 6.9M | 7.5M | 6.0M |
| General & Admin Expense | 9.2M | 9.4M | 6.9M | 7.5M | 6.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 28.9M | 27.6M | 19.8M | 22.9M | 19.2M |
| Cost and Expenses | 28.9M | 27.6M | 19.8M | 22.9M | 19.2M |
| Operating Income (EBIT) | (28.9M) | (27.6M) | (19.8M) | (22.9M) | (19.2M) |
| Non-Operating | |||||
| Interest Income | (110.0K) | 1.1M | 847.0K | 637.0K | 149.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | (110.0K) | 1.1M | 847.0K | 637.0K | 149.0K |
| Other Non-Op Income/Expense | 1.0M | 1.1M | 847.0K | 637.0K | 149.0K |
| Non-Operating Income (excl Interest) | 51.0K | (1.1M) | (847.0K) | (637.0K) | (149.0K) |
| EBT (Pre-Tax Income) | (27.8M) | (26.4M) | (19.0M) | (22.3M) | (19.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (27.8M) | (26.4M) | (19.0M) | (22.3M) | (19.1M) |
| Earnings from Cont. Ops | (27.8M) | (26.4M) | (19.0M) | (22.3M) | (19.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.3M) | (28.9M) | (19.0M) | (22.3M) | (19.1M) |
| Per Share | |||||
| Basic EPS | ($1.31) | ($1.32) | ($1.11) | ($1.43) | ($1.51) |
| Diluted EPS | ($1.31) | ($1.32) | ($1.11) | ($1.43) | ($1.51) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 23.5M | 21.8M | 17.1M | 15.6M | 12.7M |
| Diluted Shares Outstanding | 23.5M | 21.8M | 17.1M | 15.6M | 12.7M |
| Profitability Metrics | |||||
| EBITDA | (28.9M) | (26.4M) | (19.0M) | (22.3M) | (19.1M) |
| D&A | — | — | — | — | — |
| EBIT | (28.9M) | (26.4M) | (19.0M) | (22.3M) | (19.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026